がん治療・がんに対する免疫細胞療法専門クリニック
www.j-immunother.com
検索
 
瀬田クリニックグループHOME > 医療従事者専用 > 文献情報 > 【免疫細胞療法について】に関する参考文献

　
　【免疫細胞療法について】に関する参考文献
　　


No.
Title Author Journal Vol&Page Year
Pub Med ID
1
腫瘍免疫学　第２版 藤原大美　 中外医学社 　　   2003 Oct
　　
2
Coley's toxin in perspective Starnes CO   Nature 357(6373):11-2. 1992
3
The bibliography of reports. Concerning the experimental clinical use of Coley toxins. Cancer Research Institute. Nauts HC Cancer Research Institute. 　　　　 1975
　　
4
Intradermal administration of lipopolysaccharide in treatment of human cancer. Goto S, Sakai S, Kera J, Suma Y, Soma GI, Takeuchi S.
Cancer Immunol Immunother 42(4):255-61. 1996
5
Trends in the safety of high dose bolus interleukin-2 administration in patients with metastatic cancer. Kammula US, White DE, Rosenberg SA. Cancer 83(4):797-805. 1998
6
Structure and expression of a cloned cDNA for human interleukin-2.
Taniguchi T, Matsui H, Fujita T, Takaoka C, Kashima N, Yoshimoto R, Hamuro J. Nature 302(5906):305-10. 1983
7
High-dose recombinant interleukin 2 in the treatment of patients with disseminated cancer. Responses, treatment-related morbidity, and histologic findings. Lotze MT, Chang AE, Seipp CA, Simpson C, Vetto JT, Rosenberg SA. JAMA 256(22):3117-24. 1986
8
Treatment of 283 consecutive patients with metastatic melanoma or renal cell cancer using high-dose bolus interleukin-2. Rosenberg SA, Yang JC, Topalian SL, Schwartzentruber DJ, Weber JS, Parkinson DR, Seipp CA, Einhorn JH, White DE. JAMA 271(12):907-13 1994
9
A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. van der Bruggen P, Traversari C, Chomez P, Lurquin C, De Plaen E, Van den Eynde B, Knuth A, Boon T.
Science 254(5038):1643-7. 1991
10
Expression of MAGE-1, MAGE-2, MAGE-3/-6 and MAGE-4a/-4b genes in ovarian tumors. Yamada A, Kataoka A, Shichijo S, Kamura T, Imai Y, Nishida T, Itoh K. Int J Cancer 64(6):388-93. 1995
11
Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells. Nestle FO, Alijagic S, Gilliet M, Sun Y, Grabbe S, Dummer R, Burg G, Schadendorf D. Nat Med. 4(3): 328-332 1998
12
A new approach to the therapy of cancer based on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2. Rosenberg SA, Lotze MT, Muul LM, Leitman S, Chang AE, Vetto JT, Seipp CA, Simpson C. Surgery 100(2): 262-272 1986
13
Adoptive immunotherapy to lower postsurgical recurrence rates of hepatocellular carcinoma: a randomised trial. Takayama T, Sekine T, Makuuchi M, Yamasaki S, Kosuge T, Yamamoto J, Shimada K, Sakamoto M, Hirohashi S, Ohashi Y, Kakizoe T.
Lancet 356(9242):1690. 2000
14
Adjuvant adoptive immunotherapy against hepatocellular carcinoma. Takayama T, Sekine T, Kondo Y, Kakizoe T, Makuuchi M. Hepatology. 28(5):1436-7 1998
15
Adoptive immunotherapy of patients with metastatic renal cell cancer using lymphokine-activated killer cells, interleukin-2 and cyclophosphamide: long-term results. Tomita Y, Katagiri A, Saito K, Imai T, Saito T, Tanikawa T, Terunuma M, Nishiyama T, Takahashi K. Int J Urol. 5(1):16-21. 1998
16
A phase III randomized study of interleukin-2 lymphokine-activated killer cell immunotherapy combined with chemotherapy or radiotherapy after curative or noncurative resection of primary lung carcinoma. Kimura H, Yamaguchi Y.
Cancer. 80(1):42-9. 1997
17
Analytical study of the clinical response to two distinct adoptive immunotherapies for advanced hepatocellular carcinoma: comparison between LAK cell and CTL therapy. Haruta I, Yamauchi K, Aruga A, Komatsu T, Takasaki K, Hayashi N, Hanyu F. J Immunother Emphasis Tumor Immunol. 19(3):218-23. 1996
18
Use of human leukocyte antigen-mismatched allogeneic lymphokine-activated killer cells and interleukin-2 in the adoptive immunotherapy of patients with malignancies. Kimoto Y, Tanaka T, Tanji Y, Fujiwara A, Taguchi T. Biotherapy. 8(1):41-50. 1994
19
Prospective randomized trial of high-dose interleukin-2 alone or in conjunction with lymphokine-activated killer cells for the treatment of patients with advanced cancer. Rosenberg SA, Lotze MT, Yang JC, Topalian SL, Chang AE, Schwartzentruber DJ, Aebersold P, Leitman S, Linehan WM, Seipp CA, et al. J Natl Cancer Inst. 85(8):622-32. 1993
20
Prolonged continuous intravenous infusion interleukin-2 and lymphokine-activated killer-cell therapy for metastatic renal cell carcinoma. Thompson JA, Shulman KL, Benyunes MC, Lindgren CG, Collins C, Lange PH, Bush WH Jr, Benz LA, Fefer A. J Clin Oncol. 10(6):960-8. 1992
21
Use of adoptive transfer of tumor-infiltrating lymphocytes alone or in combination with cisplatin-containing chemotherapy in patients with epithelial ovarian cancer. Aoki Y, Takakuwa K, Kodama S, Tanaka K, Takahashi M, Tokunaga A, Takahashi T. Cancer Res. 51(7):1934-9. 1991
22
Intraperitoneal lymphokine-activated killer-cell and interleukin-2 therapy for malignancies limited to the peritoneal cavity. Steis RG, Urba WJ, VanderMolen LA, Bookman MA, Smith JW 2nd, Clark JW, Miller RL, Crum ED, Beckner SK, McKnight JE, et al. J Clin Oncol. 8(10):1618-29. 1990
23
Transcatheter arterial injection of autologous lymphokine-activated killer (LAK) cells into patients with liver cancers. Komatsu T, Yamauchi K, Furukawa T, Obata H. J Clin Immunol. 10(3):167-74. 1990
24
Complete remission of recurrent glioblastoma multiforme following local infusions of lymphokine activated killer cells. Case report. Naganuma H, Kimurat R, Sasaki A, Fukamachi A, Nukui H, Tasaka K. Acta Neurochir (Wien). 99(3-4):157-60. 1989
25
Immunotherapy of patients with advanced cancer using tumor-infiltrating lymphocytes and recombinant interleukin-2: a pilot study. Topalian SL, Solomon D, Avis FP, Chang AE, Freerksen DL, Linehan WM, Lotze MT, Robertson CN, Seipp CA, Simon P, et al. J Clin Oncol. 6(5):839-53. 1988
26
Immunotherapy of hepatocellular carcinoma with autologous lymphokine-activated killer cells and/or recombinant interleukin-2. Ishikawa T, Imawari M, Moriyama T, Ohnishi S, Matsuhashi N, Suzuki G, Takaku F. J Cancer Res Clin Oncol. 114(3):283-90. 1988
27
A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone. Rosenberg SA, Lotze MT, Muul LM, Chang AE, Avis FP, Leitman S, Linehan WM, Robertson CN, Lee RE, Rubin JT, et al. N Engl J Med. 316(15):889-97. 1987
28
A new approach to the therapy of cancer based on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2. Rosenberg SA, Lotze MT, Muul LM, Leitman S, Chang AE, Vetto JT, Seipp CA, Simpson C. Surgery. 100(2):262-72. 1986
29
Six-year disease-free survival of a patient with metastatic eyelid squamous cell carcinoma and colon adenocarcinoma after repeated postoperative adoptive immunotherapy. Kawamura A Jr, Sekine T, Sekiguchi M, Yanoma S, Kaneko A, Haneda T, Moriya Y, Hayasaka K, Kakizoe T. Jpn J Clin Oncol. 30(6):267-71. 2000
30
特集 　エビデンスに基づいたバイオセラピーの 有用性 　『 活性化 リンパ 球 』 高山 忠利 Biotherapy 16(1)61-64 2002
　　
31
特集 当科における 活性化自己リンパ 球移入療法の治療成績 　（ 第 13 回 日本バイオセラピー学術 総会 ワークショップ) 小川 健治 Biotherapy 15(3)217 2001
　　
32
特集 【 癌免疫療法 －21 世紀 に 向 かって－】　 癌特異的免疫療法 －CTL 療法の現状と将来 －　QOLからみた自己腫瘍特異的養子免疫療法 の意義 谷 眞至 、 谷村 弘 、 山裕 機 癌 治療と宿主 316(15)889-897 2000
　　
33
癌集学的治療における ex vivo cell therapyの意義 山口 佳之 癌治療と宿主 12(2)172-178 2000
　　
34
古層化CD3抗体活性化リンパ球を用いた悪性脳腫瘍の治療経験 渋井 荘一郎 BCG・BRM 療法 誌 23　39-45 1999
　　
35
慢性C型肝炎および肝癌の活性化自己リンパ球投与治療 関根 暉彬 化学 療法 の 領域 15(3)（399）65-(403)69 1999
　　
36
CTL 療法 有賀 淳 血液・腫瘍科 38(1)45-52 1999
　　
37
胞巣状軟部肉腫肺転移症例に対する養子免疫療法 加藤洋一 Biotherapy 12(5)685-687 1998
　　
38
術後のCBDCA、DTIC、VDS療法および養子免疫療法を施行ひた外陰および膣のⅢ期悪性黒色腫の1例 竹田 省 Biotherapy 11(4)567-570 1997
　　
39
進行 卵巣 癌 に 対する 活性化 T Cell(CD3-AT)を 用 いた 養子 免疫 療法 の 治療 効果 竹田 省 J. Jpn. Society Therapy. 30(7)967-971 1995
　　
40
Combined immunotherapy using interferon-alpha, interleukin-2 and lymphokine-activated killer cells--improvement of quality of life in patients with advanced renal cell carcinoma Watanabe J, Hattori T, Satoh M, Akimoto M. Nippon Hinyokika Gakkai Zasshi. 86(6):1156-63. 1995
41
Effect of local administration of lymphokine-activated killer cells and interleukin-2 on malignant brain tumor patients. Ibayashi Y, Yamaki T, Kawahara T, Daibo M, Kubota T, Uede T, Tanabe S, Hashi K. Neurol Med Chir (Tokyo). 33(7):448-57. 1993
42
Adoptive immunotherapy in patients with multiple hepatic cancers using lymphokine activated killer cells (LAK) and interleukin-2 Kanai T, Monden M, Takeda T, Gotoh M, Sakon M, Umeshita K, Hasuike Y, Sakita I, Nakano H, Yoshida T, et al. Gan To Kagaku Ryoho. 20(11):1457-60 1993
43
Study of adoptive immunotherapy for metastatic renal cell carcinoma with lymphokine-activated killer (LAK) cells and interleukin-2. II. Clinical evaluation Nomura K, Fujioka T.
Nippon Hinyokika Gakkai Zasshi. 84(5):831-40. 1993
44
Recurrence with tumor bleeding in a patient with malignant astrocytoma during the treatment with intracranial injection of lymphokine-activated killer cells--a case report Nagane M, Oyama H, Shibui S, Nomura K. No To Shinkei. 45(6):547-51. 1993
45
LAK cell adoptive immunotherapy and its problems Yamaguchi Y, Takayama T, Kawami H, Sato Y, Baba N, Kuroi K, Toge T. Nippon Geka Gakkai Zasshi. 92(9):1234-6. 1991
46
Usefulness and limitation of immunotherapy of metastatic renal cell carcinoma with autologous lymphokine-activated killer cells and interleukin 2 Nakano E, Iwasaki A, Seguchi T, Sugao H, Tada Y, Matsuda M, Sonoda T. Nippon Hinyokika Gakkai Zasshi. 82(3):395-404. 1991
47
固 層 化 CD3 抗体 により 活性化 したT Cell(CD3-LAK)を 用 いた 養子 免疫 療法 関根 暉彬 Biotherapy 4(10)1606-1613 1990
　　
48
Study on adoptive immunotherapy in patients with renal cell carcinoma. II. Plasmapheresis with adoptive immunotherapy using LAK cells and IL-2 Usui A. Nippon Hinyokika Gakkai Zasshi. 81(7):1058-64. 1990
49
Cultivation of human tumor infiltrating lymphocytes for use in adoptive immunotherapy Sekine T, Kakizoe T, Tobisu K, Takai K, Tanaka Y, Makuuchi M, Takayama T. Gan To Kagaku Ryoho. 16(4 Pt 2-2):1469-73. 1989
50
Clinical efficacy of LAK cell adoptive immunotherapy in advanced cancer patients Toge T, Takayama T, Kegoya Y, Kuninobu H, Yamaguchi Y, Hattori T. Nippon Geka Gakkai Zasshi. 90(9):1455-8. 1989
51
The effects of localized therapy with postsurgical local recurrences of lung carcinoma and metastatic lung tumors--laser irradiation, IL-2+ LAK or ethanol injection Baba M, Yamaguchi Y, Fujisawa T, Kimura H. Gan To Kagaku Ryoho. 15(4 Pt 2-2):1342-50. 1988
52
Prognostic significance of adoptive immunotherapy with tumor-associated lymphocytes in patients with advanced gastric cancer: a randomized trial. Kono K, Takahashi A, Ichihara F, Amemiya H, Iizuka H, Fujii H, Sekikawa T, Matsumoto Y. Clin Cancer Res. 8(6):1767-71. 2002
53
Life-prolonging effect of immunocell BAK (BRM-activated killer) therapy for advanced solid cancer patients: prognostic significance of serum immunosuppressive acidic protein levels. Ebina T, Ogama N, Shimanuki H, Kubota T, Isono N. Cancer Immunol Immunother. 52(9):555-60. 2003
54
Induction of autologous tumor-specific cytotoxic T cells in patients with liver cancer. Characterizations and clinical utilization. Aruga A, Yamauchi K, Takasaki K, Furukawa T, Hanyu F. Int J Cancer. 49(1):19-24. 1991
55
Distribution and therapeutic effect of intraarterially transferred tumor-infiltrating lymphocytes in hepatic malignancies. A preliminary report. Takayama T, Makuuchi M, Sekine T, Terui S, Shiraiwa H, Kosuge T, Yamazaki S, Hasegawa H, Suzuki K, Yamagata M, et al. Cancer. 68(11):2391-6. 1991
56
Locoregional cellular immunotherapy for patients with advanced esophageal cancer. Toh U, Yamana H, Sueyoshi S, Tanaka T, Niiya F, Katagiri K, Fujita H, Shirozou K, Itoh K. Clin Cancer Res. 6(12):4663-73. 2000
57
Chemo-immunotherapy and chemo-adoptive immunotherapy of cancer. Gomez GG, Hutchison RB, Kruse CA. Cancer Treat Rev. 27(6):375-402. 2001
58
Prolonged disease-free period in patients with advanced epithelial ovarian cancer after adoptive transfer of tumor-infiltrating lymphocytes. Fujita K, Ikarashi H, Takakuwa K, Kodama S, Tokunaga A, Takahashi T, Tanaka K. Clin Cancer Res. 1(5):501-7. 1995
59
Cancer Mortality and Morbidity statistics. Minaga S, Oshima A, et al 日本 癌学会 雑誌 174-175 1999
　　
60
膵臓 全国 登録 調査 報告 （20年間の統括） 膵臓 登録 委員会 膵臓 18:97-169 2003
　　
61
Adoptive immunotherapy for unresectable or recurrent pancreatic cancer, using lymphokine-activated killer cells or cytotoxic T cells Oka Masaaki, Suzuki Kichinari, et al Journal of Hepato-Biliary Pancreatic Surgery 2:163-167 1994
　　
62
Adoptive immunotherapy for pancreatic cancer, using MUC1 specific CTL Masaki Y, Oka M. Gan To Kagaku Ryoho. 23(12):1679-80. 1996
63
Effect of intraportal adoptive immunotherapy on liver metastases after resection of pancreatic cancer. Kobari M, Egawa S, Shibuya K, Sunamura M, Saitoh K, Matsuno S. Br J Surg. 87(1):43-8. 2000
64
膵 癌 に 対 する 養子 免疫 療法 鈴木 道成 、 岡 正朗 、 他 胆 と 膵 16:509-516 1995
　　
65
Cancer immunotherapy: moving beyond current vaccines. Rosenberg SA, Yang JC, Restifo NP. Nat Med. 10(9):909-15. 2004